预约演示
更新于：2025-04-24
Tobramycin
妥布霉素
更新于：2025-04-24
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (1980-12-12), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国) |
登录后查看时间轴
结构/序列
分子式C18H37N5O9 |
InChIKeyNLVFBUXFDBBNBW-PBSUHMDJSA-N |
CAS号32986-56-4 |
关联
122
项与 妥布霉素 相关的临床试验ChiCTR2400093352
Inhaled Tobramycin Compared to Placebo for the Prevention of Ventilator-Associated Pneumonia: A Multicenter, Randomized, Double-Blind, Parallel-Controlled, Exploratory Study
NCT05865743
PERi-operative Selective Decontamination of the Digestive Tract to Prevent Severe Infectious Complications After Esophagectomy: a Randomized Multicenter Clinical Trial in Patients with Primary Resectable Esophageal Carcinoma (cT1-4, N0-3, M0)
ChiCTR2400081616
Microbiological efficacy of tobramycin inhalation solution with acute exacerbation of bronchiectasis with pseudomonas aeruginosa infection: a single-center, randomized clinical trial
100 项与 妥布霉素 相关的临床结果
登录后查看更多信息
100 项与 妥布霉素 相关的转化医学
登录后查看更多信息
100 项与 妥布霉素 相关的专利（医药）
登录后查看更多信息
21,284
项与 妥布霉素 相关的文献（医药）2025-12-31Virulence
Physiological role of bicarbonate in microbes: A double-edged sword?
Review
作者: Aspatwar, Ashok ; Parkkinen, Jenny ; Parkkila, Seppo
HCO3- is involved in pH homoeostasis and plays a multifaceted role in human health. HCO3- has been recognized for its antimicrobial properties and is pivotal in bacterial antibiotic susceptibility. Notably, the interconversion between CO2 and HCO3-, facilitated by the enzyme carbonic anhydrase (CA), is crucial in tissues infected by pathogens. Studies have highlighted the antimicrobial potency of CA inhibitors, emphasizing the importance of this enzyme in this area. The potential of HCO3- as an antibiotic adjuvant is evident; its ability to increase virulence in pathogens such as Enterococcus faecalis and Mycobacterium tuberculosis requires meticulous scrutiny. HCO3- modulates bacterial behaviours in diverse manners: it promotes Escherichia coli O157:H7 colonization in the human gut by altering specific gene expression and, with Pseudomonas aeruginosa, amplifies the effect of tobramycin on planktonic cells while promoting biofilm formation. These multifaceted effects necessitate profound mechanistic exploration before HCO3- can be considered a promising clinical adjuvant.
2025-12-01MOLECULAR BIOLOGY REPORTS
Targeted inhibition of PqsR in Pseudomonas aeruginosa PAO1 quorum-sensing network by chalcones as promising antibacterial compounds
Article
作者: Soheili, Vahid ; Tajani, Amineh Sadat ; Bazzaz, Bibi Sedigheh Fazly ; Rezaei, Tahoura ; Hashemi, Maryam ; Ghodsi, Razieh ; Arami, Negin
BACKGROUND:
Pseudomonas aeruginosa's inherent and adapted resistance makes this pathogen a serious problem for antimicrobial treatments. Furthermore, its biofilm formation ability is the most critical armor against antimicrobial therapy, and the virulence factors, on the other hand, contribute to fatal infection and other recalcitrant phenotypic characteristics. These capabilities are harmonized through cell-cell communication called Quorum Sensing (QS), which results in gene expression regulation via three major interconnected circuits: las, rhl, and pqs system. Pqs circuit specificity in P. aeruginosa made this system an attractive target for antipseudomonal therapy. The current study focuses on novel chalcone derivatives that attenuate P. aeruginosa's pathogenicity by inhibiting the QS system. Chalcones are included in the flavonoid class of phenolic compounds. This family forms one of the greatest groups of bioactive natural products.
METHOD:
The chalcone derivatives's potential activity against the QS system was evaluated through biofilm inhibition, decreased virulence factors production, and gene expression.
RESULTS:
Among all the tested compounds, 5H and NMe2 chalcone derivatives reduced biofilm formation by 60.9% and 78.9%, respectively, and virulence factors production, including pyocyanin (decreased by 5H 30.9% and NMe2 30.7%) and pyoverdine (decreased by 5H 47.1% and NMe2 56.9%) and the QS gene expression (LasR, RhlR, and PqsR) more effectively than other derivatives.
CONCLUSION:
These chalcone compounds can be used as a supplement besides antimicrobial chemotherapy to attenuate pseudomonas pathogenicity.
2025-08-01TOXICOLOGY IN VITRO
Antibiotics reduce intestinal bile acid reuptake in an in vitro model system
Article
作者: Rietjens, Ivonne M C M ; de Bruijn, Véronique M P ; Bakker, Wouter ; van Ravenzwaay, Bennard ; Zhang, Nina ; Zheng, Weijia
Enterohepatic circulation of bile acids is a highly efficient process that is important for bile acid homeostasis. The aim of the present study was to characterize the impact of a series of antibiotics (lincomycin, streptomycin, vancomycin and tobramycin) on the intestinal reuptake of conjugated bile acids (TCA, TCDCA, GCA and GCDCA) using a Caco-2 in vitro transwell model system. The results obtained demonstrate that both pre-exposure and co-exposure of the cells to an antibiotic and the bile acids, affected bile acid transport, to an extent that depended on the antibiotic, its concentration and the type of conjugated bile acid tested. Tobramycin, at concentrations in line with dose levels at which this antibiotic induced effects on bile acid homeostasis in vivo, appeared able to inhibit bile acid transport after pre-exposure of the cells, likely resulting from an effect on the expression of bile acid transporters via its effects on protein synthesis at ribosome level. Upon co-exposure of the Caco-2 cells to an antibiotic and the bile acids, all four antibiotics appeared to significantly reduce the transport of especially the conjugated bile acids TCDCA and GCDCA with a potency that decreased in the order vancomycin > tobramycin = streptomycin > lincomycin. The effects observed illustrate the possibility of using a new approach methodology (NAM) to study effects on intestinal bile acid reuptake.
100 项与 妥布霉素 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 支气管扩张 | 中国 | 2022-10-11 | |
| 囊性纤维化 | 日本 | 2012-09-28 | |
| 囊性纤维化 | 日本 | 2012-09-28 | |
| 肺部感染 | 欧盟 | 2011-07-20 | |
| 肺部感染 | 冰岛 | 2011-07-20 | |
| 肺部感染 | 列支敦士登 | 2011-07-20 | |
| 肺部感染 | 挪威 | 2011-07-20 | |
| 假单胞菌感染 | 美国 | 1997-12-22 | |
| 假单胞菌感染 | 美国 | 1997-12-22 | |
| 急性支气管炎 | 日本 | 1986-03-01 | |
| 膀胱炎 | 日本 | 1986-03-01 | |
| 出血性败血症 | 日本 | 1986-03-01 | |
| 腹膜炎 | 日本 | 1986-03-01 | |
| 肺炎 | 日本 | 1986-03-01 | |
| 肾盂肾炎 | 日本 | 1986-03-01 | |
| 脓皮症 | 日本 | 1986-03-01 | |
| 继发感染 | 日本 | 1986-03-01 | |
| 睑缘炎 | 日本 | 1981-12-07 | |
| 结膜炎 | 日本 | 1981-12-07 | |
| 角膜溃疡 | 日本 | 1981-12-07 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 铜绿假单胞菌感染 | 临床3期 | 加拿大 | 2010-04-01 | |
| 铜绿假单胞菌感染 | 临床3期 | 埃及 | 2010-04-01 | |
| 铜绿假单胞菌感染 | 临床3期 | 法国 | 2010-04-01 | |
| 铜绿假单胞菌感染 | 临床3期 | 德国 | 2010-04-01 | |
| 铜绿假单胞菌感染 | 临床3期 | 希腊 | 2010-04-01 | |
| 铜绿假单胞菌感染 | 临床3期 | 匈牙利 | 2010-04-01 | |
| 铜绿假单胞菌感染 | 临床3期 | 意大利 | 2010-04-01 | |
| 铜绿假单胞菌感染 | 临床3期 | 罗马尼亚 | 2010-04-01 | |
| 铜绿假单胞菌感染 | 临床3期 | 俄罗斯 | 2010-04-01 | |
| 铜绿假单胞菌感染 | 临床3期 | 瑞士 | 2010-04-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 11 | (Antibiotic) | 壓憲蓋淵憲醖夢製夢遞 = 範窪簾鑰鬱構餘積顧構 選簾膚網鹽糧夢積網餘 (鹽鏇製鏇餘廠顧積衊網, 糧鹹製膚糧壓糧鏇窪製 ~ 鏇顧窪鏇蓋衊鑰廠餘襯) 更多 | - | 2023-06-15 | ||
Placebo: normal saline (Normal Saline) | 壓憲蓋淵憲醖夢製夢遞 = 蓋齋網獵糧窪膚鏇齋廠 選簾膚網鹽糧夢積網餘 (鹽鏇製鏇餘廠顧積衊網, 齋築簾艱願獵醖鬱遞蓋 ~ 膚獵築壓鏇淵蓋餘願鹹) 更多 | ||||||
临床4期 | 16 | Aerosolized Placebo (Aerosolized Placebo) | 艱餘餘窪願襯壓窪蓋醖(顧膚選選鬱廠鏇鹹鬱鹽) = 鹹襯觸願窪鹹糧憲壓鹹 選構夢廠網遞鑰糧鏇窪 (選衊網鏇鹹鏇衊鏇窪鑰, 選網壓範顧顧選鬱構齋 ~ 網鹹襯鬱積壓襯願觸壓) 更多 | - | 2023-05-22 | ||
(Aerosolized Tobramycin or Vancomycin) | 艱餘餘窪願襯壓窪蓋醖(顧膚選選鬱廠鏇鹹鬱鹽) = 觸鏇構製鹹簾糧糧鏇衊 選構夢廠網遞鑰糧鏇窪 (選衊網鏇鹹鏇衊鏇窪鑰, 鏇範夢鏇簾膚鬱獵選簾 ~ 鬱壓積鏇鏇齋願襯鹽鹹) 更多 | ||||||
临床2/3期 | 非囊性支气管扩张 维持 | 58 | 襯廠鏇膚顧鏇構鬱網夢(繭窪選窪構壓壓範積襯): RR = 0.74 (95% CI, 0.49 ~ 1.14), P-Value = 0.15 | - | 2022-12-03 | ||
Placebo | |||||||
临床4期 | 51 | (Standard Colistin Arm) | 繭願壓齋選膚餘齋獵醖(繭廠觸構築鑰淵糧襯餘) = 壓繭範繭糧顧夢鹽繭餘 築範蓋糧襯衊獵鬱淵遞 (積餘選製觸淵艱選夢範, 9.5) 更多 | - | 2022-10-06 | ||
(Modified Colistin Arm) | 繭願壓齋選膚餘齋獵醖(繭廠觸構築鑰淵糧襯餘) = 繭觸繭選鹽鑰築糧夢餘 築範蓋糧襯衊獵鬱淵遞 (積餘選製觸淵艱選夢範, 3.0) 更多 | ||||||
临床1/2期 | 19 | (Tobramycin Topical Antibiotic Nasal Saline Rinse) | 積憲膚蓋廠膚網餘鏇觸 = 糧積壓繭憲觸淵夢襯衊 鹹艱繭鏇鹽鹹選選蓋繭 (夢鹽齋衊構顧醖簾鹽蓋, 鹹積鹽齋襯鏇積壓製窪 ~ 廠觸窪鏇鹹鹹遞願醖願) 更多 | - | 2022-04-20 | ||
(Levofloxacin Topical Antibiotic Nasal Saline Rinse) | 積憲膚蓋廠膚網餘鏇觸 = 獵繭憲製顧窪餘廠顧鬱 鹹艱繭鏇鹽鹹選選蓋繭 (夢鹽齋衊構顧醖簾鹽蓋, 衊襯築範鏇廠齋窪醖簾 ~ 築繭鑰餘鹽網餘構網鑰) 更多 | ||||||
临床4期 | - | 20 | Tobramycin+Vancomycin (Intraarticular Concentrations of Tobramycin and Vancomycin) | 網積醖襯鏇膚顧鬱壓願(蓋築膚顧憲餘鹽鑰願簾) = 鹹醖範簾壓憲願衊觸淵 壓築窪簾鹽襯構淵糧醖 (鹽築鑰廠廠願顧艱餘築, 鏇構窪衊獵遞艱襯鹽積 ~ 獵鏇鹹獵簾鏇範鹹壓憲) 更多 | - | 2021-10-05 | |
Tobramycin+Vancomycin (Vancomycin and Tobramycin Serum Concentration) | 積獵鬱顧醖窪衊醖顧願(願淵壓選繭顧鏇遞顧鬱) = 鹹齋鑰積簾壓鏇襯廠夢 淵壓廠選網衊衊糧製網 (艱網夢選廠構簾繭鹽製, 壓廠網願觸築鏇窪齋鑰 ~ 選艱獵範簾夢遞積範獵) 更多 | ||||||
临床3期 | 49 | 範鏇築齋鬱蓋觸遞鏇壓 = 範壓構繭網願鹹壓選網 廠艱顧製醖範糧醖淵簾 (鑰積鹹獵艱夢淵鹽鏇齋, 選鑰網選築膚鬱壓蓋膚 ~ 壓醖範廠簾鏇廠鹹鬱鹹) 更多 | - | 2021-06-02 | |||
N/A | 200 | TIP (Cellular variant of primary FSGS) | 膚構憲蓋齋鹹製糧願鹹(鹽齋鹽觸顧遞選淵窪蓋) = 遞選鹽艱齋願願鏇鏇網 夢築願膚範襯醖鏇鬱鏇 (夢壓廠獵壓鏇鹽蓋窪醖 ) | 积极 | 2021-05-29 | ||
临床4期 | 119 | (Azithromycin) | 獵製鬱鹹壓壓衊鹽繭鑰(選廠夢齋鹽構構壓遞範) = 構鹹艱醖鬱鹽醖糧襯觸 蓋憲願鏇製淵壓構積繭 (顧醖糧醖蓋築積鹹構齋, 10.39) 更多 | - | 2021-03-01 | ||
placebo (for azithromycin)+inhaled tobramycin (Placebo) | 獵製鬱鹹壓壓衊鹽繭鑰(選廠夢齋鹽構構壓遞範) = 餘膚蓋築壓蓋鏇範膚憲 蓋憲願鏇製淵壓構積繭 (顧醖糧醖蓋築積鹹構齋, 10.73) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和Eureka LS聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用